Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ALEC
Strong SellSinkerAlector, Inc. · Healthcare · United States · $261M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Alector, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for neurodegenerative diseases. The company's research focuses on modulating the immune system in the brain to treat conditions like Alzheimer's and Parkinson's. Its pioneering approach to neuroimmunology offers a unique therapeutic strategy in a field with significant unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 133.6M | 97.1M | 100.6M | 21.0M | -46.0% | 13.9M | 11.0M | 26.2M | 11.5% |
| EPS | -1.62 | -1.56 | -1.23 | -1.39 | — | -1.09 | -0.86 | -0.75 | — |
| Shares | 82.9M | 84.9M | 99.1M | 110.4M | +33.1% | 111.7M | — | — | — |
| Debt | 43.3M | 38.9M | 42.5M | 36.2M | -5.8% | 32.8M | — | — | — |
| Equity | 214.4M | 134.2M | 126.8M | 30.6M | -47.7% | — | — | — | — |
| Op CF | -20.3M | -184.2M | -229.9M | -184.0M | — | -158.2M | — | — | — |
| Inv CF | -159.0M | 101.9M | 107.1M | 196.6M | — | — | — | — | — |
| Fin CF | 4.5M | 2.5M | 81.5M | 20.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALEC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ALEC | Alector, Inc.(you) | $261M | 5 | Strong Sell |
| NMRA | Neumora Therapeutics, Inc. | $261M | 5 | Strong Sell |
| LCTX | Lineage Cell Therapeutics, Inc. | $281M | 5 | Strong Sell |
| GLSI | Greenwich LifeSciences, Inc. | $230M | 4 | Strong Sell |
| SRZN | Surrozen, Inc. | $264M | 9 | Strong Sell |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | $260M | 10 | Strong Sell |
| AVXL | Anavex Life Sciences Corp. | $277M | 9 | Strong Sell |
| TRDA | Entrada Therapeutics, Inc. | $273M | 10 | Strong Sell |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $211M | 7 | Strong Sell |
| TARA | Protara Therapeutics, Inc. | $226M | 9 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%